Abstract-On the basis of the patterns of conserved amino acid sequence, the angiotensin II type 2 (AT 2 ) receptor belongs to the family of serpentine receptors, which relay signals from extracellular stimuli to heterotrimeric G proteins. However, the AT 2 receptor signal transduction mechanisms are poorly understood. We have measured AT 2 -triggered activation of purified heterotrimeric proteins in urea-extracted membranes from cultured COS-7 cells expressing the recombinant receptor. This procedure removes contaminating GTP-binding proteins without inactivating the serpentine receptor. Binding studies using [ 125 I] angiotensin (Ang) II revealed a single binding site with a K d ϭ0.45 and a capacity of 627 fmol/mg protein in the extracted membranes. The AT 2 receptor caused a rapid activation of ␣ i and ␣ o but not of ␣ q and ␣ s , as measured by radioactive guanosine 5Ј-3-O-(thio)triphosphate (GTP␥S) binding. Activation required the presence of activated receptors, ␤␥, and ␣ subunits. As a first step aimed at developing an in vitro assay to examine AT 2 receptor pharmacology, we tested a battery of Ang II-related ligands for their ability to promote AT 1 or AT 2 receptor-catalyzed G i activation. Two proteolytic fragments of Ang II, Ang III and Ang1-7, also promoted activation of ␣ i through the AT 2 receptor. Furthermore, we found that [Sar 1 ,Ala 8 ]Ang II is an antagonist for both AT 1 and AT 2 receptors and that CPG42112 behaves as a partial agonist for the AT 2 receptor. In combination with previous observations, these results show that the AT 2 receptor is fully capable of activating G i and provides a new tool for exploring AT 2 receptor pharmacology and interactions with G-protein trimers. (Ang II) is the primary effector of the renin/angiotensin system. This 8-amino acid peptide is a key regulator of blood pressure and body fluid homeostasis and plays a critical role in the pathophysiology of several cardiovascular diseases such as hypertension, hypertrophy, and congestive heart failure. 1 In particular, blocking the effects of Ang II with the use of angiotensin-converting enzyme inhibitors or losartan (a competitive AT 1 antagonist) is used in treatment of cardiovascular diseases. To understand the Ang II signal transduction pathways, it will be important to examine the individual components of the system. Two Ang II receptor subtypes, type 1 (AT 1 ) 2 and type 2 (AT 2 ) receptors, 3 have been identified. The AT 1 receptor has a widespread tissue distribution and mediates most of the known cardiovascular Ang II functions including vasoconstriction and cardiac and vascular hypertrophy. 4 The expression pattern of the AT 2 receptor is more restricted and suggests that this receptor plays a role in growth, development, and differentiation. The AT 2 is highly expressed in fetal tissues, whereas in adults, it is confined to organs such as heart, vascular smooth muscle, brain, adrenal cortex, uterus, and ovarian follicles. 4 AT 2 activation dilates blood vessels, inhibits growth, and induces apoptosis. 1 In addition, the AT 2 receptor plays a role in neuronal differentiation and regeneration 5 and is upregulated in skin wounds, blood vessel neointima on injury, and during cardiac remodeling after a myocardial infaction. 4 The AT 2 receptor, like the AT 1 receptor, contains seven stretches of hydrophobic amino acids, a hallmark of the family of serpentine receptors. This large family of surface receptors relays extracellular signals from hormones and sensory stimuli to heterotrimeric G proteins at the cytoplasmic face of the plasma membrane. The serpentine receptors activate G proteins by promoting exchange of GTP for GDP bound to the ␣ subunit of the heterotrimer, causing liberation of both ␣-GTP and free ␤␥ complexes, which in turn activate effector enzymes and ion channels. 6 On the basis of sequence homology and intracellular effector regulation, 16 distinct mammalian ␣ subunits have been subclassified into four subfamilies, ␣ i1/2/3 , ␣ t , ␣ z , that (except ␣ z ) are pertussis toxin
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Which signaling proteins or G proteins does the AT 2 receptor activate to exert its biological functions? It has proven difficult to ascertain whether AT 2 receptors activate heterotrimeric G proteins in vivo. 7 Several reports indicate that the AT 2 receptor may couple to G i . Thus, in rat hippocampal neurons and a few other cell types, blocking ␣ i with PTX or antibodies directed against ␣ i inhibits the AT 2 receptor effects. 8 -10 In two studies, a direct interaction between AT 2 receptors and ␣ i was inferred from coimmunoprecipitation experiments. 10 In contrast, in neuroblastoma cells and NG108-15 cells bearing AT 2 receptors, PTX does not block Ang II effects. 11 Moreover, in PC-12 cells bearing endogenous AT 2 receptors and in HEK293 or COS-7 cells overexpressing AT 2 receptors, Ang II does not apparently change intracellular concentrations of cAMP, cGMP, or inositol phosphates. 3 These results suggest that the AT 2 receptor does not activate ␣ q , ␣ i , or ␣ s and raise the question whether this receptor uses G proteins as signaling partners.
To examine whether the AT 2 receptor can activate G i , we have assessed in vitro AT 2 -G i interactions in a solution of urea-washed membranes from AT 2 -transfected COS-7 cells containing purified G-protein components. 12, 13 The AT 2 receptor triggered activation of G-protein subunits (␣ i and ␤␥), as ascertained by guanosine 5Ј-3-O-(thio)triphosphate (GTP␥S) binding. Ligand-activated AT 2 stimulated GTP␥S binding to G i and G 0 , but not G s or G q . We infer from our results that AT 2 receptors directly activate ␣ i and ␣ o . The fidelity and degree of resolution of the interaction allow structure function studies and further AT 2 receptor pharmacological characterization. 
Materials and Methods

Materials
Construction of the R142A-AT 2 Receptor
The point mutation was generated by polymerase chain reaction in two steps with Pfu polymerase with the wild-type receptor cDNA as a probe, as described. 13 
Cell Culture and Transfection
COS-7 cells were maintained in DME-H21 medium containing 10% FCS, 2.5 g/mL Fungizone, and 10 g/mL gentamycin. Transient transfections with wild-type serpentine receptors were performed using a DEAE-dextran/adenovirus method as described. 13 
Membrane Preparation
Membranes from COS-7 cells transfected with cDNAs encoding human AT 2 , human PTH, or human ␤ 2 receptors were prepared as described. 13 Membrane microsomal fractions, obtained by centrifugation, were stripped of GTP-binding proteins as described 12 by incubation in 6 mol/L urea.
G-Protein Purification
Alpha subunits were purified from Sf9 cell membranes infected with baculovirus encoding the wild-type protein, His 6 -tagged ␥ 2 , and wild-type ␤ 1 as described. 14 
Ligand Binding
Binding of [ 125 I]Ang II was determined as described. 15 Binding was initiated by suspending urea-extracted membranes in a mixture of [ 125 I]Ang II (100 pmol/L), cold Ang II, and a buffer consisting of 25 mmol/L Tris-HCl, pH 7.3, 100 mmol/L NaCl, 5 mmol/L MgCl 2 , 1 mmol/L EDTA, 2 mg/mL BSA, 0.1 mg/mL bacitracin, and 50 g/mL soybean trypsin inhibitor.
G␣ Activation
Exchange of GTP␥S for GDP bound to G␣s was measured using a modification of a previously described procedure. 16 Briefly, membranes containing receptors (Ϸ5 nmol/L) were preincubated with purified ␣s (50 nmol/L) and ␤␥ (100 nmol/L) for 15 minutes on ice in a buffer containing 20 mmol/L Na-HEPES, pH 7.6, 1 mmol/L Tris-HCl, pH 7.6, 100 mmol/L NaCl, 2 mmol/L MgCl 2 , 1 mol/L GDP, and 1 mmol/L ␤-mercaptoethanol. Assays were initiated by addition of agonist and [ 
Mitogen-Activated Protein Kinase (MAPK) Phosphorylation
COS-7 cells were cotransfected with plasmids encoding the AT 2 receptor, ␣ i2 , ␤ 2 , and ␥ 1 . After transfection, the cells were incubated in DMEM supplemented with 10% FCS overnight followed by 16 hours of serum starvation. Next, the cells were stimulated with 10% FCS for 12 minutes in the presence and absence of Ang II. Cell lysates and quantification of MAPK phosphorylation was performed as described. 17
Elk1 Activation
Transcriptional activation of Elk1 luciferase expression by MAPK was assessed by cotransfecting pFA2-Elk1, plasmids encoding pFR-luc, ␤-galactosidase (␤-Gal), and the AT 2 receptor, ␣ i2 , ␤ 2 , and ␥ 1 expression plasmids in COS-7 cells. After transfection, the cells were incubated in DMEM supplemented with 10% FCS overnight. Next, the cells were serum-starved for Ϸ16 hours followed by a 24-hour incubation with 10% serum in the presence and absence of 100 nmol/L Ang II. Luciferase and ␤-Gal activities were measured as described by the manufacturer.
Results
To examine the AT 2 -receptor/G-protein coupling, we used urea-extracted COS-7 cell membranes transiently expressing AT 2 receptors and compared the results with those previously reported for other receptors: rhodopsin, gastrin-releasing peptide, PTHR, or ␤ 2 AR. 12, 13 The addition of purified G-protein subunits (both ␣ i and ␤␥) allowed us to examine the selectivity of G-protein activation and assess the potency of Ang II-related receptor ligands.
Ligand Binding Studies
Urea-treated COS-7 cell membranes bearing the wild-type AT 2 receptor or a specific mutant R142A (a mutation that uncouples receptor-G-protein activation) 18 were analyzed for Ang II binding. Figure 1 
Receptor Activation Assay
To assess AT 2 -mediated activation of ␣ i , we measured liganddependent binding of radioactive GTP␥S in a mixture containing pure ␣ i and ␤␥ and urea-washed membranes from COS-7 cells expressing recombinant receptors and NIH3T3 cells bearing native AT 2 receptors. In both of these systems, Ang II induced significant GTP␥S binding only in the presence of receptors ␣ i and ␤␥ (Figures 2B and 2D) . In urea-treated COS-7 membranes, Ang II increased GTP␥S binding 3-to 10-fold in different experiments. At maximal stimulation, radioactive GTP␥S bound to 10% to 30% of the total ␣ i present in the assay. The effect of Ang II was complete within 3 minutes (not shown). This shows that the AT 2 receptor can catalyze the exchange of GDP for GTP␥S on ␣ i . To explore the effects of urea treatment, we compared GTP␥S binding in P2 membranes and urea-washed membranes from COS-7 and NIH3T3 cells (Figure 2) . Ang II induced a 7% and 19% increase in GTP␥S binding in COS-7 and NIH3T3 P2 membranes, respectively. Coexpression of ␣ i and ␤␥ did not improve the Ang II effect (Figure 2 ). These results show that with native complement of G proteins, there is a trend toward AT 2 activation-enhanced GTP binding, although the signal-to-noise is hampered by the high level of AT 2 -uncoupled GTP-binding proteins. The data also show that urea treatment drastically reduces endogenous GTP binding without inactivating the recombinant serpentine receptors consistent with previous findings. 12 Figure 3 depicts the concentration dependence of the individual components of the system. The kinetics of G-protein activation would be expected to be saturable with each of the components. This prediction was fulfilled: GTP␥S binding was saturable with increasing concentrations of ␣ i while keeping the ␤␥ concentrations fixed at 250 nmol/L ( Figures 3A and 3B) . The K 0.5 for ␣ i was Ϸ24 nmol/L. Similarly, the GTP␥S binding was saturable in the converse experiment, increasing the ␤␥ concentrations at fixed concentrations of ␣ i ( Figure 3B ). In addition, the GTP␥S binding was ligand-dependent ( Figure 4A To test the specificity of ␣ i activation, we examined the ability of AT 2 receptors to activate three additional ␣ subunits, ␣ 0 , ␣ q , and ␣ s . G␣ 0 is a brain ␣ i -like subunit. G␣ q activates PLC, and ␣ s is the stimulatory regulator of adenylyl cyclase. Both of these ␣ subunits have no resemblance to ␣ i in primary structure. The AT 2 activated ␣ 0 and ␣ i but failed to promote GTP␥S binding on ␣ q and ␣ s ( Figure 4B ). Two other serpentine receptors, PTHR and ␤ 2 AR, activated ␣ s , and the AT 1 receptor activated ␣ q , confirming the functionality of these added ␣ subunits ( Figure 4C ). Furthermore, a point mutation of arginine (R142A-AT 2 ) in the conserved DRY sequence at the COOH-terminal part of ic2 produced a receptor that could not activate G i , suggesting that AT 2 receptors activate G proteins by similar mechanisms as other receptors. 18 These experiments show that AT 2 receptors discriminate between G i , G q , and G s in this system. Another important question is whether the added ␣ i might be activated by a serpentine receptor. We examined this using membranes expressing PTHR. The activated PTHR did not promote GDP exchange for GTP␥S on ␣ i ( Figure 4B ). Thus, both the recombinant AT 2 and the purified ␣ i have retained specificity in this system.
AT 2 Receptor Pharmacology
We examined the effect of different Ang II analogues on AT 1 and AT 2 receptor-induced ␣ i activation. Figure 5 shows that in addition to Ang II, one of its proteolytic fragments, Ang III (desAsp 1 -Ang II), behaved as an agonist on both AT 1 and AT 2 receptors. Ang1-7 selectively activated AT 2 receptors albeit with a much lower affinity than Ang II. Ang1-7 is another Ang II proteolytic fragment found in plasma. This peptide induces bradykinin-mediated hypotensive responses and reduces smooth muscle growth after vascular injury. 20, 21 Thus, AT 2 receptors could be responsible for these actions. CGP42112A, a pseudo-peptide that binds the AT 2 receptor with high affinity and selectivity, was initially considered an antagonist. 7 Our results using this compound alone suggest that CGP42112A is a selective AT 2 agonist. A similar conclusion was previously made. 17 However, in the presence of 100 nmol/L Ang II, a high concentration of CGP42112A works antagonistically and thus inhibits the effect of Ang II ( Figure 5B ). These data suggest that CGP42112A is a partial agonist. Losartan and PD123319, two nonpeptidic Ang II analogues, bind with high affinity and selectivity to AT 1 and AT 2 receptors, respectively. 22 Accordingly, losartan selectively blocked AT 1 activity in the described assay ( Figure 5 ). Olmesartan and candesartan also selectively blocked AT 1 receptor activity (data not shown). In almost all reported AT 2 -mediated effects, PD123319 is a selective competitive antagonist (Table) . In our study, this compound selectively blocked AT 2 receptor activity. In addition, an antagonist [Sar 1 ,Ala 8 ]-Ang II, thought to block both receptors, did so in our assays ( Figure 5 ).
AT 2 Receptor Effects in Intact COS-7 Cells
Given that our assay is a reconstitution of purified G proteins with urea-washed COS-7 membranes, we wanted to analyze whether the transfected AT 2 receptor could activate signaling pathways in intact cells. The AT 2 receptor has been reported to couple to ERK1/2 MAPK phosphorylation. To explore this concept, we investigated MAPK (ERK1/2) phosphorylation by Western blotting and MAPK transcriptional activation of Elk1 using Elk1 luciferase reporter plasmid. AT 2 receptor activation induced both MAPK phosphorylation and Elk1 luciferase ex- pression in the presence of serum compared with the effect of serum alone (Figure 6 ). AT 2 receptor activation did not affect MAPK phosphorylation or activation in the absence of serum (not shown). These data show that AT 2 receptor activation in COS-7 cells is functionally coupled to MAPK.
Discussion
We have set up a system to assay AT 2 receptor activation of G i to understand the G-protein signaling properties of this receptor. The AT 2 receptor has diverse biological effects in cell growth, differentiation, and control of blood vessel tone (Table) . However, the molecular events behind these effects have not been clearly defined. In particular, it has not been possible to document G protein-regulated activation of classical second messengers such as cAMP and the phospho-inositide metabolism. 3 Almost all other serpentine receptors regulate at least one of these systems. Can the AT 2 receptor activate G proteins? To answer this question, we tested the ability of the AT 2 receptor to activate the ␣ subunit of G i in a reconstituted system. In this system, the AT 2 receptor activated ␣ i in a manner dependent on the concentrations of ligand, receptor, and G i subunits. These results suggest that the AT 2 receptor activates G i in much the same way as other receptors activate G proteins. In similar assays, rhodopsin activates transducin, and the gastrin-releasing peptide receptor activates G q . 12, 18 Mutations can produce promiscuous receptors, which activate classes of G proteins not activated by the parent wild-type receptors. 23 Could the described assay simply unmask an inherent promiscuity of AT 2 receptors? To address this question, we performed two experiments, the results of which suggested that the assay does exhibit specificity. First, the AT 2 receptor was unable to induce GTP␥S binding to purified G q and G s , two different G proteins, and vice versa, the G i was not activated by PTHR.
Data from ligand binding studies, use of PTX, which inactivates ␣ i , and coimmunoprecipitation experiments using anti-G-protein antibodies, support the inference that the AT 2 receptor activates G proteins. First, GTP␥S reduces AT 2 receptor binding affinity in certain cell membranes and in HEK293 cells with overexpressed AT 2 receptors. 3, 11 Second, at least three AT 2 -mediated biological effects are blocked by PTX: a delayed rectified K current in neurons, 8 inhibition of NIH3T3 cell growth, 9 and DNA synthesis in vascular smooth muscle cells. 10 Third, AT 2 receptor protein has been coimmunoprecipitated with ␣ i from fetal rat cells 24 and vascular smooth muscle cells, 10 suggesting that a physical association exists. AT 2 receptor activation also promotes PTXinsensitive cellular events (Table) . Our results show that the AT 2 receptor can support activation of G i and G 0 but not G q and G s .
AT 2 Receptor Signal Transduction in Different Cellular Environments
If the AT 2 receptor activates G i , why does it not inhibit cAMP production or robustly activate MAPK, effects attributed to activation of ␣ i and liberation of ␤␥? 7, 22 Our results do not unequivocally answer this question; however, possible explanations can be offered. First, in at least three reports, AT 2 receptor stimulation led to MAPK phosphatase-1 (MKP-1) activation, an effect that prevents MAPK activation (Table) . 10 Moreover, we ( Figure 6 ) and others suggest that the AT 2 receptor can activate MAPK in COS-7 cells and NG108-15 cells, the latter after prolonged stimulation. 17 It is possible that in these cells, MKP-1 is expressed at lower levels or that its regulation in NG108-15 cells is time-dependent, ie, an initial activation that inhibits MAPK followed by its inactivation, resulting in MAPK activation. Second, the AT 2 receptor could need an unknown protein to organize G proteins and second messengers in its vicinity. Third, the repertoire and concentration of resident G proteins in a given cell type may modify receptor coupling. It is possible that, in vivo, the AT 2 receptor couples to G␣ i with a low affinity or with a low rate of GDP-GTP exchange. Thus, only cells expressing high levels of AT 2 and G␣ i would produce detectable levels of second messengers. Fourth, cell-specific posttranslational modifications of the AT 2 receptor could play a role in determining G-protein specificity.
Our simple assay proved useful for the determination of AT 2 receptor pharmacology, something that has been difficult to evaluate because of the lack of reproducible and easily quantifiable effects. We compared different peptidic and nonpeptidic Ang II analogues on AT 2 -induced G␣ i activation. Furthermore, to validate our observations, we tested the same battery of analogues on membranes bearing AT 1 receptors, for which responses to these ligands are well characterized. 7 We found that Ang II and its proteolytic fragment Ang III (lacks the amino-terminal Asp) act as agonists on the AT 2 receptor. Similarly, and as expected, 22 they also triggered AT 1 -induced G␣ i activation.
In one study, Ang1-7, an Ang II proteolytic fragment in which the carboxyl-terminal residue is cleaved, was reported to induce prostaglandin synthesis in human astrocytes through AT 2 receptors. 25 Moreover, evidence suggests that Ang II proteolytic fragments other than Ang III and including Ang1-7 may have some biological activities. 7 Accordingly, we found that this peptide selectively activated the AT 2 receptor. Taken together, these results suggest that, in vivo, both Ang II and Ang III could serve as agonists for the AT 2 receptor given that they have similar affinities. 7
